These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11705445)

  • 21. Hyperkalemia: a threat to RAAS inhibition?
    Schrier RW
    Nat Rev Nephrol; 2010 May; 6(5):245-6. PubMed ID: 20424624
    [No Abstract]   [Full Text] [Related]  

  • 22. [Let's read the domestic literature. ACE-inhibitors and spironolactone-induced hyperkalemia].
    Radó J
    Orv Hetil; 2002 Aug; 143(31):1868; author reply 1868. PubMed ID: 12187583
    [No Abstract]   [Full Text] [Related]  

  • 23. Influence of combined angiotensin-converting enzyme inhibitors and spironolactone on serum K+, Mg 2+, and Na+ concentrations in small dogs with degenerative mitral valve disease.
    Thomason JD; Rockwell JE; Fallaw TK; Calvert CA
    J Vet Cardiol; 2007 Nov; 9(2):103-8. PubMed ID: 17983885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Junctional escape rhythm secondary to acute hyperkalemic renal failure in the setting of concurrent beta-blocker therapy.
    Isabel J; Champion JC
    JAAPA; 2006 Dec; 19(12):78. PubMed ID: 17243264
    [No Abstract]   [Full Text] [Related]  

  • 25. Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort.
    Abbas S; Ihle P; Harder S; Schubert I
    Pharmacoepidemiol Drug Saf; 2015 Apr; 24(4):406-13. PubMed ID: 25683504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.
    Juurlink DN; Mamdani MM; Lee DS; Kopp A; Austin PC; Laupacis A; Redelmeier DA
    N Engl J Med; 2004 Aug; 351(6):543-51. PubMed ID: 15295047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Life-threatening hyperkalaemia caused by angiotensin-converting enzyme-inhibitor and diuretics.
    Odawara M; Asano M; Yamashita K
    Diabet Med; 1997 Feb; 14(2):169-70. PubMed ID: 9047098
    [No Abstract]   [Full Text] [Related]  

  • 28. [Effects of the RALE study. Hyperkalemia following spironolactone treatment].
    Erdmann E
    Internist (Berl); 2005 Apr; 46(4):466, 468. PubMed ID: 15723149
    [No Abstract]   [Full Text] [Related]  

  • 29. Prevalence of hyperkalemia in adult patients taking spironolactone and angiotensin converting enzyme inhibitors or angiotensin receptor blockers.
    Surabenjawong U; Thunpiphat N; Chatsiricharoenkul S; Monsomboon A
    J Med Assoc Thai; 2013 Aug; 96(8):905-10. PubMed ID: 23991595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
    Am J Cardiol; 1996 Oct; 78(8):902-7. PubMed ID: 8888663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-induced hyperkalaemia is frequent.
    Prescrire Int; 2007 Feb; 16(87):16. PubMed ID: 17323523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preventable sudden death in patients receiving angiotensin converting enzyme inhibitors and loop/potassium sparing diuretic combinations.
    Johnston RT; de Bono DP; Nyman CR
    Int J Cardiol; 1992 Feb; 34(2):213-5. PubMed ID: 1737674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of spironolactone in heart failure patients receiving angiotensin-converting enzyme inhibitors and beta-blockers.
    Ahmed A
    J Am Coll Cardiol; 2003 May; 41(10):1851-2. PubMed ID: 12767683
    [No Abstract]   [Full Text] [Related]  

  • 34. Combined use of an ACE-inhibitor and spironolactone in patients with heart insufficiency.
    Schröder J; Goltz L; Knoth H
    Med Monatsschr Pharm; 2017 Jan; 40(1):24-6. PubMed ID: 29952529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Renal effect of treatment for heart failure].
    Rasmussen ZZ; Barfod T; Klit J
    Ugeskr Laeger; 2009 Feb; 171(9):718. PubMed ID: 19257999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spironolactone for heart failure.
    Med Lett Drugs Ther; 1999 Sep; 41(1061):81-2. PubMed ID: 10505071
    [No Abstract]   [Full Text] [Related]  

  • 37. Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.
    Ray K; Dorman S; Watson R
    J Hum Hypertens; 1999 Oct; 13(10):717-20. PubMed ID: 10516744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estimation of glomerular filtration rate to prevent life-threatening hyperkalemia due to combined therapy with spironolactone and angiotensin-converting enzyme inhibition or angiotensin receptor blockade.
    Blaustein DA; Babu K; Reddy A; Schwenk MH; Avram MM
    Am J Cardiol; 2002 Sep; 90(6):662-3. PubMed ID: 12231102
    [No Abstract]   [Full Text] [Related]  

  • 39. Spironolactone in patients with heart failure.
    Fernandez HM; Leipzig RM
    N Engl J Med; 2000 Jan; 342(2):132; author reply 133-4. PubMed ID: 10636750
    [No Abstract]   [Full Text] [Related]  

  • 40. Spironolactone in patients with heart failure.
    Larkin RJ; Atlas SA; Donohue TJ
    N Engl J Med; 2000 Jan; 342(2):132-3; author reply 133-4. PubMed ID: 10636751
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.